Regulation of Immune Cells by microRNAs and microRNA-Based Cancer Immunotherapy

Veiga, Rafaela Nasser; Zambalde, Érika Pereira; Cox, Livia; Jucoski, Tayana Shultz; Kohler, Ana Flávia; Carvalho, Tamyres Mingorance; Rodrigues, Ana Carolina; Ludwig, Beatriz; Crowley, Kaitlyn; Oliveira, Jaqueline Carvalho de; Cortez, María Angélica

doi:10.1007/978-3-031-08356-3_3

Cited by 3 publications

(2 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dolz et al found that miR-17-92 is closely related to the proliferation of CD4 + T cells [21] . Veiga et al found that miR-155 is a key positive regulator of regulatory T cells (Tregs) [22] . At the same time, studies have shown that miRNAs play an important role in hematopoietic differentiation, which is related to the cellular immune response leading to ITP [23] .…”

Section: And Figmentioning

confidence: 99%

Analysis of the Mechanism of T Lymphocytes Promoting Immune Platelet Transfusion Refractoriness by Gene Chip Technique

Song¹,

Luo²,

Wang³

et al. 2023

IJPS

View full text Add to dashboard Cite

The main objective of this study is to analyze the expression levels of messenger ribonucleic acid and long non-coding ribonucleic acid in patients with platelet transfusion refractoriness and reveal the mechanism of T lymphocytes in immune platelet transfusion refractoriness. The Agilent expression profile chip was used to detect the expression levels; gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on the differential genes to determine their main biological functions. Unsupervised hierarchical clustering was used to process differential genes and the differential genes among samples were represented in a heat map. The differentially expressed messenger ribonucleic acids and long non-coding ribonucleic acids in different groups were found as 720 and 1719 in normal control group vs. platelet transfusion effective group; 4254 and 12491 in normal control group vs. platelet transfusion ineffective group and 1806 and 6216 in platelet transfusion effective group vs. platelet transfusion ineffective group. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on differentially expressed genes, and the results were annotated to be related to T cells. The co-expression of the target gene Ras-related protein 1A and long non-coding transactive response deoxyribonucleic acid binding protein 2 was determined through the national center for biotechnology information database and the interaction between micro ribonucleic acid-4739 and Ras-related protein 1A was predicted using the starBase and TargetScan databases. T lymphocytes play an important role in immune platelet transfusion refractoriness and long non-coding transactive response deoxyribonucleic acid binding protein 2 may affect the differentiation of T lymphocytes and promote the occurrence of immune platelet transfusion refractoriness through micro ribonucleic acid-4739 targeting Rasrelated protein 1A gene regulation.

show abstract

Section: And Figmentioning

confidence: 99%

Analysis of the Mechanism of T Lymphocytes Promoting Immune Platelet Transfusion Refractoriness by Gene Chip Technique

Song¹,

Luo²,

Wang³

et al. 2023

IJPS

View full text Add to dashboard Cite

show abstract

“…miRNAs are convenient diagnostic, prognostic and therapeutics markers of various human diseases (e.g., cardiovascular, metabolic, neurologic, infectious) [ 8 , 9 , 10 , 11 , 12 ] and cancers [ 13 , 14 , 15 , 16 ]. In addition, miRNAs are increasingly recognized as modulators of disease pathogeneses and are consequently considered bona fide molecular therapeutic targets [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

Thibonnier

Ghosh

2023

IJMS

View full text Add to dashboard Cite

We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institutions. Our aim is to develop safe, effective and convenient active targeting miRNA ONT agents for the metabolic pandemic of obesity and metabolic-associated fatty liver disease (MAFLD), as well as deadly ovarian cancer.

show abstract